Phase II study of nivolumab in Japanese patients with relapsed or refractory Hodgkin lymphoma previously treated with brentuximab vedotin (ONO-4538-15): An interim analysis.

被引：3
|
作者：
Hatake, Kiyohiko
Kinoshita, Tomohiro
Fukuhara, Noriko
Choi, Ilseung
Taniwaki, Masafumi
Ando, Kiyoshi
Maruyama, Dai
Terui, Yasuhito
Higuchi, Yusuke
Onishi, Yasushi
Abe, Yasunobu
Kobayashi, Tsutomu
Shirasugi, Yukari
Tobinai, Kensei
机构：
[1] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Hematol & Oncol, Tokyo, Japan
[2] Aichi Canc Ctr, Dept Hematol & Cell Therapy, Nagoya, Aichi, Japan
[3] Tohoku Univ, Grad Sch Med, Dept Hematol & Rheumatol, Sendai, Miyagi, Japan
[4] Natl Hosp Org Kyushu Canc Ctr, Dept Hematol, Fukuoka, Japan
[5] Kyoto Prefectural Univ Med, Univ Hosp, Div Hematol & Oncol, Kyoto, Japan
[6] Tokai Univ, Dept Hematol & Oncol, Isehara, Kanagawa, Japan
[7] Natl Canc Ctr, Dept Hematol, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e19018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19018
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged ≥60 Years
    Yasenchak, Christopher A.
    Bordoni, Rodolfo
    Yazbeck, Victor
    Patel-Donnelly, Dipti
    Anderson, Thomas
    Larson, Timothy
    Newhook, Trevor
    Mei, Matthew
    Ho, Linda
    Friedberg, Jonathan W.
    BLOOD, 2019, 134
  • [42] 2-Year Follow-Up Results From the Phase 1-2 Study of Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 10 - 11
  • [43] Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study
    Izutsu, Koji
    Ogura, Michinori
    Tobinai, Kensei
    Hatake, Kiyohiko
    Sakamoto, Shigeru
    Nishimura, Masanori
    Hoshino, Miyako
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (03) : 404 - 412
  • [44] Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study
    Koji Izutsu
    Michinori Ogura
    Kensei Tobinai
    Kiyohiko Hatake
    Shigeru Sakamoto
    Masanori Nishimura
    Miyako Hoshino
    International Journal of Hematology, 2021, 113 : 404 - 412
  • [45] Phase I/II study of brentuximab vedotin in pediatric patients (pts) with relapsed or refractory (RR) Hodgkin lymphoma (HL) or systemic anaplastic large-cell lymphoma (sALCL): Interim phase (ph) I safety data
    Neville, Kathleen
    Gore, Lia
    Mauz-Koerholz, Christine
    Rosolen, Angelo
    Landman-Parker, Judith
    de Toledo, Jose Sanchez
    Beishuizen, Auke
    Franklin, Anna Rachel Keating
    Fasanmade, Adedigbo
    Wang, Jingyuan
    Huebner, Dirk
    Locatelli, Franco
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [46] Brentuximab Vedotin in Combination with Bendamustine in Relapsed or Refractory Hodgkin Lymphoma: A Retrospective Analysis on 23 Paediatric Patients or Young Adults
    Vinti, Luciana
    Locatelli, Franco
    Merli, Pietro
    Parasole, Rosanna
    Buffardi, Salvatore
    Pillon, Marta
    Strocchio, Luisa
    Girardi, Katia
    BLOOD, 2017, 130
  • [47] TARC Predicts PET-Normalization and Event Free Surival in Relapsed/Refractory Hodgkin Lymphoma Patients Treated with Brentuximab Vedotin
    Moskowitz, Alison J.
    Cho, Sun
    Fleisher, Martin
    Woo, Kaitlin M.
    Zhang, Zhigang
    Fox, Stephanie
    McCall, Susan J.
    Schoder, Heiko
    Yahalom, Joachim
    Moskowitz, Craig H.
    BLOOD, 2015, 126 (23)
  • [48] Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study
    Stamatoullas, Aspasia
    Ghesquieres, Herve
    Feugier, Pierre
    Andre, Marc
    Le Bras, Fabien
    Gac, Anne-Claire
    Borel, Cecile
    Gastinne, Thomas
    Quittet, Philippe
    Morschhauser, Franck
    Ribrag, Vincent
    Guidez, Stephanie
    Nicolas-Virelizier, Emmanuelle
    Berriolo-Riedinger, Alina
    Vander Borght, Thierry
    Edeline, Veronique
    Brice, Pauline
    LEUKEMIA & LYMPHOMA, 2022, 63 (13) : 3063 - 3071
  • [49] Brentuximab Vedotin Plus Bendamustine for Pediatric Patients with Relapsed/Refractory Hodgkin Lymphoma: A Multi-Institution Retrospective Analysis
    Forlenza, Christopher J.
    Gulati, Nitya
    Mauguen, Audrey
    Absalon, Michael J.
    Castellino, Sharon M.
    Franklin, Anna
    Keller, Frank G.
    Shukla, Neal
    BLOOD, 2020, 136
  • [50] Brentuximab vedotin in the treatment of paediatric patients with relapsed or refractory Hodgkin's lymphoma: Results of a real-life study
    Massano, Davide
    Carraro, Elisa
    Mussolin, Lara
    Buffardi, Salvatore
    Barat, Veronica
    Zama, Daniele
    Muggeo, Paola
    Vendemini, Francesca
    Sau, Antonella
    Moleti, Maria Luisa
    Verzegnassi, Federico
    D'Amico, Salvatore
    Casini, Tommaso
    Garaventa, Alberto
    Schiavello, Elisabetta
    Cellini, Monica
    Vinti, Luciana
    Farruggia, Piero
    Perruccio, Katia
    Cesaro, Simone
    De Santis, Raffaela
    Marinoni, Maddalena
    D'Alba, Irene
    Mura, Rosa Maria
    Burnelli, Roberta
    Mascarin, Maurizio
    Pillon, Marta
    PEDIATRIC BLOOD & CANCER, 2022, 69 (10)
12345